PURE Bioscience (PURE) Reports Study Showing Effectiveness of SDC Against Biofilm

May 19, 2011 (Business Wire) — PURE Bioscience, Inc. (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced preliminary in vitro laboratory results demonstrating SDC’s effectiveness against biofilm in tests conducted by the University of Medicine & Dentistry of New Jersey.

Dr. Narayanan Ramasubbu, Associate Professor, Department of Oral Biology, stated, “We have used SDC against single species biofilms of Aggregatibacter actinomycetemcomitans, a causative agent in localized aggressive periodontitis, and S. epidermidis, a pathogen associated with hospital settings. Our results show that these bacteria in the biofilm state are killed within minutes at 30 ppm of SDC. Not only did SDC kill biofilm bacteria but also it inhibited the biofilm formation at levels as low as 1.5 ppm in a citrate-containing medium.”

According to Dr. Ramasubbu, biofilm bacteria predominate, numerically and metabolically, in virtually all nutrient-sufficient ecosystems, including the oral cavity. Biofilms play a role in the pathogenesis of dental caries, periodontitis, infective endocarditis, cystic fibrosis, pneumonia, prostatitis, osteomyelitis, otitis media, infectious kidney stones and other chronic infections. Bacterial cells in a biofilm are surrounded by a self-synthesized, three-dimensional matrix (slime or extracellular polysaccharide, EPS) that holds the cells together in a mass and firmly attaches the bacterial mass to a range of living and non-living surfaces.

Dr. Ramasubbu also explained that the exopolysaccharide mediates resistance to killing by antibiotics, detergents and antimicrobial peptides. However, bacteria in the biofilm can survive because of channels in them that circulate nutrients and water. Biofilms can be comprised of a single microbial species or multiple microbial species and eradicating them requires very specific, highly effective and environmentally safe agents that can adapt to the resistance.

Michael L. Krall, President and CEO of PURE Bioscience, commented, “SDC’s ability to eliminate and even prevent biofilm presents a phenomenal market opportunity for PURE. We’re directing ongoing research projects on biofilm not only in public health, but also in industrial environments, including food processing, and oil and gas, as we begin to present SDC as a viable solution to this costly and dangerous problem.”

SDC is a new molecular entity, developed and patented worldwide by PURE Bioscience. An electrolytically generated source of stabilized ionic silver in liquid form, SDC provides superior antimicrobial efficacy with residual protection while mitigating bacterial resistance. SDC is colorless, odorless, tasteless, non-toxic and formulates well with other compounds, making it an ideal basis for a broad range of products. SDC is available in pre-formulated, ready-to-use products; including PURE’s disinfectant and food contact surface sanitizer, and is also available in varying strengths of concentrate for use as an additive or raw material.

About PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s cash position and liquidity requirements, acceptance of the Company’s current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience Investor Contact:

Lippert/Heilshorn & Associates

Don Markley, Senior Vice President

310-691-7100

dmarkley@lhai.com

or

PURE Bioscience Media Contact:

Gutenberg Communications

Michael Gallo

212-239-8594

mgallo@gutenbergpr.com